Theravance Biopharma, Inc. (TBPH)
NASDAQ: TBPH · Real-Time Price · USD
16.67
+0.19 (1.15%)
May 13, 2026, 4:00 PM EDT - Market closed
Theravance Biopharma Stock Forecast
Stock Price Forecast
The 5 analysts that cover Theravance Biopharma stock have a consensus rating of "Buy" and an average price target of $18.4, which forecasts a 10.38% increase in the stock price over the next year. The lowest target is $15 and the highest is $24.
Price Target: $18.4 (+10.38%)
Analyst Consensus: Buy
* Price targets were last updated on Apr 7, 2026.
Analyst Ratings
The average analyst rating for Theravance Biopharma stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 3 | 3 | 3 |
| Buy | 1 | 1 | 1 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| B. Riley Securities | B. Riley Securities | Hold Maintains $14 → $17 | Hold | Maintains | $14 → $17 | +1.98% | Apr 7, 2026 |
| TD Cowen | TD Cowen | Hold Maintains $13 → $15 | Hold | Maintains | $13 → $15 | -10.02% | Mar 23, 2026 |
| BTIG | BTIG | Strong Buy Reiterates $21 | Strong Buy | Reiterates | $21 | +25.97% | Mar 20, 2026 |
| Oppenheimer | Oppenheimer | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Mar 5, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $27 → $15 | Strong Buy | Maintains | $27 → $15 | -10.02% | Mar 4, 2026 |
Financial Forecast
Revenue This Year
108.40M
from 107.46M
Increased by 0.87%
Revenue Next Year
87.70M
from 108.40M
Decreased by -19.10%
EPS This Year
1.92
from 2.06
Decreased by -6.91%
EPS Next Year
0.43
from 1.92
Decreased by -77.34%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 191.6M | 94.1M | ||||||
| Avg | 108.4M | 87.7M | ||||||
| Low | 75.9M | 77.2M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 78.3% | -13.2% | ||||||
| Avg | 0.9% | -19.1% | ||||||
| Low | -29.4% | -28.8% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 |
|---|---|---|---|---|---|---|
| High | 2.18 | 0.74 | ||||
| Avg | 1.92 | 0.43 | ||||
| Low | 1.48 | 0.15 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 |
|---|---|---|---|---|---|---|
| High | 6.0% | -61.6% | ||||
| Avg | -6.9% | -77.3% | ||||
| Low | -28.2% | -92.3% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.